Status:
COMPLETED
Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence
Lead Sponsor:
Advanz Pharma
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 month...
Eligibility Criteria
Inclusion
- Inclusion Criteria (partial list):
- Subjects must have sustained, symptomatic atrial fibrillation for greater than 72 hours and less than 6 months duration
- Subjects must have adequate anticoagulant therapy
- Exclusion Criteria (partial list):
- Subjects may not have Class III or Class IV congestive heart failure
- Subjects may not have uncorrected electrolyte imbalance
Exclusion
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
221 Patients enrolled
Trial Details
Trial ID
NCT00267930
Start Date
December 1 2005
End Date
August 1 2006
Last Update
December 18 2008
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
The Heart Center, P.C.
Huntsville, Alabama, United States, 35801
2
Cardiovascular Consultants Medical Group, Inc.
Walnut Creek, California, United States, 94598
3
Penn State Heart & Vascular Institute
Hershey, Pennsylvania, United States, 17033
4
Marshfield Clinic
Marshfield, Wisconsin, United States, 54449